Navigation Links
BioXcel Launches Its Flagship Product, PharmGPS™
Date:4/22/2013

Branford, CT (PRWEB) April 22, 2013

BioXcel Corporation, coinciding with the BIO International 2013 Convention in Chicago, announced the launch of PharmGPS™, a “first-in-class,” dynamic analytics platform with customizable apps, built to address complex investment decisions across the biopharmaceutical industry stakeholder value-chain.

“Decision making and knowledge management paradigms are fragmented and becoming increasingly complex with the explosion of data and a rapidly evolving healthcare ecosystem,” said Dr. Vimal Mehta, BioXcel’s Chairman. “PharmGPS™ provides an innovative solution to revolutionize decision making with a unified platform for actionable decisions thereby optimizing investments and enhancing the probability of success.

PharmGPS™ is a disease-area focused, analytics engine encompassing all major and specialty therapeutic areas. Using a patient-centric approach, PharmGPS™ assesses each disease indication for the best window of commercial opportunity, dynamic probability of technical and regulatory success, forecasting, and scenario analysis. This applies to both in-market and pipeline drugs, satisfying the future standard of care in each disease indication/segment. “BioXcel’s long-term commitment to developing PharmGPSTM has been supported by multiple clients working to meet patient needs,” said Dr. Krishnan Nandabalan, BioXcel’s President & CEO. “We are vigorously expanding current indications and commercializing this exciting new product to a wide biopharmaceutical audience.”

The platform is built on several years’ experience, deep domain expertise, commercially validated frameworks, and proprietary processes for generating insights and recommendations. The analytics engine operates on dynamic specialized data sets, each structured by experts from medical, clinical, scientific, commercial, and intellectual property disciplines. It also allows stakeholders to leverage internal organic and confidential data via customized, downloadable “apps” backed by BioXcel’s expert consulting and technology services. Multiple teams’ decision-journeys will be empowered by PharmGPS™, ranging from strategy, business development/licensing, research & development, and commercial development/branding.

About BioXcel
BioXcel Corporation is a leading, analytics-based consulting company that provides 360° decision support solutions through its expert services and analytics enabled platform, PharmGPS™. BioXcel has grown steadily as an analytics and consulting partner during the last seven years, serving the biopharmaceutical industry exclusively.
BioXcel Corporation is headquartered in Branford, CT, USA.

Contact:
Dr. Krishnan Nandabalan
780 East Main Street
Branford, CT 06405
http://www.bioxcel.com
Phone: 203 433 4086
Mobile: 203 606 3000
Email: knandabalan(at)bioxcel(dot)com

Read the full story at http://www.prweb.com/releases/2013/4/prweb10655380.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
2. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
3. BioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer
4. Ambry Genetics Launches Illumina MiSeq Next-Gen Sequencing Services
5. Neogen Launches Fully Quantitative Lateral Flow Test for DON
6. Exagen Diagnostics Launches Cutting-Edge Lupus Diagnostic
7. iHealth Lab Launches Personalized Web Portal to Store Your Vitals
8. Elsevier Launches Bilingual International Nursing Skill Training and Management Platform: NursingChina.com
9. Upsher-Smith Launches B-Nexa® Prescription Prenatal Vitamin With B Vitamins and Ginger for Nausea and Vomiting of Pregnancy
10. bioTheranostics Launches Precision Medicine Biomarkers for Tumor Pathway Interrogation
11. ERT Launches New Website to Support Significant Commercial Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... announced the launch of the Supplyframe Design Lab . Located in Pasadena, ... explore the future of how hardware projects are designed, built and brought to ...
Breaking Biology Technology:
(Date:6/22/2016)... June 22, 2016  The American College of Medical Genetics ... Executive Magazine as one of the fastest-growing trade shows ... at the Bellagio in Las Vegas . ... percentage of growth in each of the following categories: net ... and number of attendees. The 2015 ACMG Annual Meeting was ...
(Date:6/22/2016)... WASHINGTON , June 22, 2016 On ... highly-anticipated call to industry to share solutions for the ... by U.S. Customs and Border Protection (CBP), explains that ... nationals are departing the United States ... criminals, and to defeat imposters. Logo - ...
(Date:6/20/2016)... 20, 2016 Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring announced ... it has secured the final acceptance by all ... Managed Access Systems (MAS) installed. Furthermore, Securus will ... be installed by October, 2016. MAS distinguishes between ...
Breaking Biology News(10 mins):